Appointments

Eleva, a clinical-stage biopharmaceutical company, has announced the appointment of Martin Bauer as its new chief medical officer.

Bauer brings more than two decades of clinical development experience to the role and has held management positions of increasing responsibility over the course of his career. He more recently held the position of senior director at Merck KGaA after serving as head of clinical research at Basilea Pharmaceutica and as medical director at ICON.

He has also held roles at Atriva Therapeutics, Otsuka and Boehringer Ingelheim, is board-certified in anaesthesiology, rescue medicine and medical informatics, and has over ten years of experience working in academic hospitals.

Commenting on his latest venture, Bauer said: “I’m thrilled to support Eleva as the company further strengthens its drug development activities with additional pipeline programmes and potentially new indications being explored.”

Bauer added that the company’s Factor H programme in particular “has the potential to unlock a novel therapeutic mode-of-action that is clearly differentiated from the standard-of-care”.

Eleva’s chief executive officer, Björn Cochlovius, said: “With the clinical trial start for our second fully owned drug development programme on the horizon, we have decided to appoint an experienced chief medical officer orchestrating all of these activities.

“[Bauer’s] deep expertise in clinical development across several indications and modalities will be very valuable for Eleva’s continued growth as a drug development organisation.”